Screening karcinomu prsu, kolorektálního karcinomu a karcinomu hrdla děložního umožňuje snížit populační mortalitu těchto onemocnění. Aby byl však skutečně zachován příznivý poměr mezi přínosy a riziky plynoucími ze screeningového programu aplikovaného na širokou populaci, je třeba zavést a dodržovat komplexní standardy kvality péče. Screeningové programy by měly být implementovány jako organizované a populační, se zajištěním kvality na všech úrovních. Cílem tohoto přehledového článku je představit systém kontroly kvality v českých programech screeningu zhoubných nádorů a uvést konkrétní příklady indikátorů kvality využitelných a využívaných v těchto programech. Programy screeningu zhoubných nádorů v ČR jsou vybaveny komplexním informačním zázemím, které zahrnuje monitoring zátěže populace zhoubnými nádory, monitoring screeningového procesu prostřednictvím klinických dat a monitoring screeningového procesu prostřednictvím administrativních dat. Konkrétní indikátory kvality popisují zejm. úspěšnost náběru cílové populace, schopnost screeningového testu objevit (senzitivita) a vyloučit (specificita) hledané onemocnění, správné využívání následné dia­gnostiky a případně léčby detekovaných zhoubných nádorů nebo prekanceróz. V programu screeningu karcinomu prsu jsou tyto indikátory rutinně využívány pro monitoring jednotlivých center, v programech screeningu kolorektálního karcinomu a karcinomu hrdla děložního jsou využívány pro monitoring celého programu a systém kontroly kvality jednotlivých center je postupně vyvíjen. Od roku 2014 byl zahájen projekt adresného zvaní, který je v současné době ve spolupráci s Národním referenčním centrem a Ministerstvem zdravotnictví ČR rovněž průběžně vyhodnocován.

Breast, colorectal and cervical cancer screening programmes make it possible to decrease the population mortality rates of these diseases. How­ever, complex standards of the quality of care must be introduced and followed in order to maintain a favourable ratio between the benefits and risks arising from population‑wide screening programmes. Such programmes should be organized and population‑based, ensuring that quality control is performed at all levels. This review introduces the system of quality control in the Czech cancer screening programmes, and provides specific examples of performance indicators that are usable and/or being used in these programmes. Cancer screening programmes in the Czech Republic are equipped with a comprehensive information background which involves monitoring of the cancer burden in the population, monitoring of the screening process based on clinical data, and monitoring of the screening process based on administrative data. In particular, the specific performance indicators describe the success rate of take‑up of the target population, ability of the screening test to reveal (sensitivity) or to exclude (specificity) the screened condition, correct employment of subsequent dia­gnostic methods or treatment of detected cancers or precancerous lesions where applicable. In the Czech breast cancer screening programme, these indicators are routinely used in order to monitor the individual centres; in both colorectal and cervical cancer screening programmes, these indicators are used to monitor the entire programme, whereas the system of quality control for individual centres is under continuous development. A project of personalized invitations was launched in 2014, and its results are regularly evaluated in cooperation with the Czech National Reference Centre and the Ministry of Health of the Czech Republic. Key words:cancer – mass screening – health care quality indicators This study was supported by the project 36/14//NAP “Development and implementation of metho­dology for the evaluation of effectiveness of personalised invitations of citizens to cancer screening programmes” as part of the program­­me of the Czech Ministry of Health “National action plans and conceptions”. The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers. Submitted: 16. 9. 2014 Accepted: 31. 10. 2014

• MeSH
• časná detekce nádoru MeSH
• kolorektální nádory * prevence a kontrola   MeSH
• lidé MeSH
• nádory děložního čípku * prevence a kontrola   MeSH
• nádory prsu * prevence a kontrola   MeSH
• plošný screening * metody   normy   organizace a řízení   MeSH
• registrace normy   MeSH
• řízení kvality MeSH
• ukazatele kvality zdravotní péče * normy   využití   MeSH
• zajištění kvality zdravotní péče MeSH
• zlepšení kvality MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• práce podpořená grantem MeSH
• přehledy MeSH

Organizovaný screening karcinomu prsu byl v ČR zahájen v roce 2002. Nedílnou součástí programu je od jeho počátku sběr údajů o screeningových mamografiích, o následné dia­gnostice a o konečné dia­gnóze. Sběr těchto dat je uložen Ministerstvem zdravotnictví ČR jako povinný pro všechna akreditovaná centra. Cílem tohoto sdělení je ukázat aktuální výsledky z monitoringu kvality center. Indikátory kvality, jejichž definice odpovídá mezinárodním standardům, se věnují účasti žen, objemu prováděných vyšetření, přesnosti screeningové mamografie, využívání předoperační dia­gnostiky a zastoupení časně detekovaných nádorů. Hodnocením indikátorů kvality lze doložit postupné zvyšování kvality mamografického screeningu v ČR, který je tak plně v souladu s mezinárodními doporučeními o zajištění kvality.

The Czech organised breast cancer screening programme was initiated in 2002. Collection of data on screening mammography examinations, subsequent dia­gnostic procedures, and final dia­gnosis is an indispensable part of the programme. Data collection is obligatory for all accredited centres, in accordance with regulations issued by the Czech Ministry of Health. This contribution aims to demonstrate the recent results of quality monitoring of the accredited centres. Quality indicators, whose definition complies with international standards, involve the women’s participation, the volume of performed examinations, the accuracy of screening mammography, the use of pre‑operative dia­gnostics, and the proportion of early detected tumours. Our evaluation documents a continuous improvement in quality of the Czech mammography screening programme, which is thereby in full agreement with international recommendations on quality assurance. Key words: breast neoplasms – mass screening – mammography – health care quality indicators This study was supported by the project 36/14//NAP “Development and implementation of metho­dology for the evaluation of effectiveness of personalised invitations of citizens to cancer screening programmes” as part of the program­­me of the Czech Ministry of Health “National action plans and conceptions”. The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers. Submitted: 18. 9. 2014 Accepted: 24. 10. 2014

• MeSH
• časná detekce nádoru statistika a číselné údaje   MeSH
• falešně negativní reakce MeSH
• hodnocení programu * metody   statistika a číselné údaje   MeSH
• interpretace statistických dat MeSH
• lidé MeSH
• mamografie statistika a číselné údaje   MeSH
• nádory prsu * diagnóza   epidemiologie   prevence a kontrola   MeSH
• pacientův souhlas se zdravotní péčí statistika a číselné údaje   MeSH
• plošný screening * statistika a číselné údaje   MeSH
• registrace statistika a číselné údaje   MeSH
• senzitivita a specificita MeSH
• ukazatele kvality zdravotní péče * statistika a číselné údaje   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika MeSH

BACKGROUND: The Czech Breast Cancer Screening Programme (CBCSP) was initiated in September 2002 by establishing a network of accredited centres. The aim of this article is to describe progress in the programme quality over time after the inception of the organised programme. METHODS: The CBCSP is monitored using an information system consisting of three principal components: 1) the national cancer registry, 2) a screening registry collecting data on all screening examinations, further assessments and final diagnoses at accredited programme centres, and 3) administrative databases of healthcare payers. Key performance indicators from the European Guidelines have been adopted for continuous monitoring. RESULTS: Breast cancer incidence in the Czech Republic has steadily been increasing, however with a growing proportion of less advanced stages. The mortality rate has recently stabilised. The screening registry includes 2,083,285 records on screening episodes between 2002 and 2008. In 2007-2008, 51% of eligible women aged 45-69 were screened. In 2008, the detection rates were 6.1 and 3.7 per 1,000 women in initial and subsequent screening respectively. Corresponding recall rates are 3.9% and 2.2%, however, it is necessary to pay attention to further assessment performed during the screening visits. Benign to malignant open biopsy ratio was 0.1. Of invasive cases detected in screening, 35.6% was less than 10 mm in diameter. Values of early performance indicators, as measured by both crude and standardized estimates, are generally improving and fulfil desirable targets set by European Guidelines. CONCLUSIONS: Mammography screening in the Czech Republic underwent successful transformation from opportunistic prevention to an organised programme. Values of early indicators confirm continuous improvement in different aspects of process quality. Further stimulation of participation through invitation system is necessary to exploit the full potential of screening mammography at the population level.

• MeSH
• hodnocení programu MeSH
• lidé středního věku MeSH
• lidé MeSH
• mamografie využití   MeSH
• nádory prsu diagnóza   MeSH
• plošný screening organizace a řízení   využití   MeSH
• podpora zdraví MeSH
• registrace MeSH
• senioři MeSH
• ukazatele kvality zdravotní péče MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika MeSH

STUDY QUESTION: Is it possible to define a set of performance indicators (PIs) for clinical work in ART, which can create competency profiles for clinicians and for specific clinical process steps? SUMMARY ANSWER: The current paper recommends six PIs to be used for monitoring clinical work in ovarian stimulation for ART, embryo transfer, and pregnancy achievement: cycle cancellation rate (before oocyte pick-up (OPU)) (%CCR), rate of cycles with moderate/severe ovarian hyperstimulation syndrome (OHSS) (%mosOHSS), the proportion of mature (MII) oocytes at ICSI (%MII), complication rate after OPU (%CoOPU), clinical pregnancy rate (%CPR), and multiple pregnancy rate (%MPR). WHAT IS KNOWN ALREADY: PIs are objective measures for evaluating critical healthcare domains. In 2017, ART laboratory key PIs (KPIs) were defined. STUDY DESIGN SIZE DURATION: A list of possible indicators was defined by a working group. The value and limitations of each indicator were confirmed through assessing published data and acceptability was evaluated through an online survey among members of ESHRE, mostly clinicians, of the special interest group Reproductive Endocrinology. PARTICIPANTS/MATERIALS SETTING METHODS: The online survey was open for 5 weeks and 222 replies were received. Statements (indicators, indicator definitions, or general statements) were considered accepted when ≥70% of the responders agreed (agreed or strongly agreed). There was only one round to seek levels of agreement between the stakeholders.Indicators that were accepted by the survey responders were included in the final list of indicators. Statements reaching less than 70% were not included in the final list but were discussed in the paper. MAIN RESULTS AND THE ROLE OF CHANCE: Cycle cancellation rate (before OPU) and the rate of cycles with moderate/severe OHSS, calculated on the number of started cycles, were defined as relevant PIs for monitoring ovarian stimulation. For monitoring ovarian response, trigger and OPU, the proportion of MII oocytes at ICSI and complication rate after OPU were listed as PIs: the latter PI was defined as the number of complications (any) that require an (additional) medical intervention or hospital admission (apart from OHSS) over the number of OPUs performed. Finally, clinical pregnancy rate and multiple pregnancy rate were considered relevant PIs for embryo transfer and pregnancy. The defined PIs should be calculated every 6 months or per 100 cycles, whichever comes first. Clinical pregnancy rate and multiple pregnancy rate should be monitored more frequently (every 3 months or per 50 cycles). Live birth rate (LBR) is a generally accepted and an important parameter for measuring ART success. However, LBR is affected by many factors, even apart from ART, and it cannot be adequately used to monitor clinical practice. In addition to monitoring performance in general, PIs are essential for managing the performance of staff over time, and more specifically the gap between expected performance and actual performance measured. Individual clinics should determine which indicators are key to the success in their organisation based on their patient population, protocols, and procedures, and as such, which are their KPIs. LIMITATIONS REASONS FOR CAUTION: The consensus values are based on data found in the literature and suggestions of experts. When calculated and compared to the competence/benchmark limits, prudent interpretation is necessary taking into account the specific clinical practice of each individual centre. WIDER IMPLICATIONS OF THE FINDINGS: The defined PIs complement the earlier defined indicators for the ART laboratory. Together, both sets of indicators aim to enhance the overall quality of the ART practice and are an essential part of the total quality management. PIs are important for education and can be applied during clinical subspecialty. STUDY FUNDING/COMPETING INTERESTS: This paper was developed and funded by ESHRE, covering expenses associated with meetings, literature searches, and dissemination. The writing group members did not receive payment.Dr G.G. reports personal fees from Merck, MSD, Ferring, Theramex, Finox, Gedeon-Richter, Abbott, Biosilu, ReprodWissen, Obseva, PregLem, and Guerbet, outside the submitted work. Dr A.D. reports personal fees from Cook, outside the submitted work; Dr S.A. reports starting a new employment in May 2020 at Vitrolife. Previously, she has been part of the Nordic Embryology Academic Team, with meetings were sponsored by Gedeon Richter. The other authors have no conflicts of interest to declare. DISCLAIMER: This document represents the views of ESHRE, which are the result of consensus between the relevant ESHRE stakeholders and where relevant based on the scientific evidence available at the time of preparation.The recommendations should be used for informational and educational purposes. They should not be interpreted as setting a standard of care, or be deemed inclusive of all proper methods of care nor exclusive of other methods of care reasonably directed to obtaining the same results. They do not replace the need for application of clinical judgment to each individual presentation, nor variations based on locality and facility type.Furthermore, ESHREs recommendations do not constitute or imply the endorsement, recommendation, or favouring of any of the included technologies by ESHRE.

• Publikační typ
• časopisecké články MeSH

Registry nepříbuzných dárců celosvětově evidují k začátku roku 2014 přes 24 milionů dobrovolných dárců a počet odběrů krvetvorných buněk ročně přesahuje 16 000. K zajištění kvality vyhledávání nepříbuzného dárce definovala pracovní skupina při Světové asociaci dárců (WMDA) klíčové ukazatele kvality, které byly retrospektivně vyhodnoceny i v rámci Českého národního registru dárců dřeně (ČNRDD). Cílem práce bylo zhodnotit plnění jednotlivých ukazatelů kvality, provést další rozbor u těch, které neodpovídají stanoveným kritériím a porovnat výsledky s publikovanými daty. Z pěti analyzovaných indikátorů kvality byly za rok 2013 úspěšně splněny tři: podíl provedených rozšířených typizací do dvou týdnů od obdržení žádosti, podíl dárců dostupných při předodběrovém vyšetření a podíl vstupně chybných typizačních výsledků zjištěných při verifikační typizaci. Nebyly splněny dva indikátory kvality: podíl vzorků dostupných dárců při verifikační typizaci (79 % u ČNRDD oproti 80 % doporučených WMDA) a podíl vzorků zaslaných k verifikační typizaci do dvou týdnů od obdržení žádosti (64 % u ČNRDD oproti 80 % doporučených WMDA). Vzhledem k těmto nesplněným indikátorům byly analyzovány důvody nedostupnosti dárce či jeho prolongovaného vyhledávání, kdy hlavní příčinou byly nedostatečné kontaktní údaje dárce. Při podrobnější analýze jsme pak identifikovali rizikovou skupinu těch dárců, kteří při vstupu do registru udali pouze poštovní adresu a telefon. Naopak nejméně nedostupných dárců bylo ve skupině těch, kteří udali e-mailový kontakt. Na základě analýzy potenciálních příčin u nesplněných indikátorů kvality byla definována možná opatření k jejich budoucímu kompletnímu splnění. Klíčová slova: transplantace, indikátor, kvalita, nepříbuzenské, registr dárců, HLA typizace

At the beginning of 2014 over 24 million of unrelated donors being listed in the registries worldwide and number of hematopoietic stem cell collections exceed 16 000 per year. In order to insure the quality of unrelated donor searches Quality Assurance Working Group at the World Marrow Donor Association defined global key performance indicators for bone marrow donor registries, which were retrospectively evaluated also within Czech National Marrow Donors Registry. The aim of the study was evaluate the performance of quality indicators, perform further analysis for those that do not meet the specified criteria and compare the observed result with published data. For the year 2013 three of the five analysed quality indicators were fulfilled: the rate of extended typing performed within two weeks of receipt of the request, the rate of donors available during work up examination and the rate of discrepant typing identified in the verification typing. Two quality indicators were not fulfilled: the rate of samples of the donors available during verification typing (79% in the CNMDR compared to 80% WMDA recommended) and the rate of samples sent for verification typing within two weeks from receipt of the request (64% in the CNMDR compared to 80% WMDA recommended). Due to this unfulfilled indicators reasons for the unavailability of the donors were analysed and the lack of contact was identified as the main reason. Looking at the detail we identified the risk group of donors with only contact address and phone number provided upon entry to the registry. On the contrary minimum of unavailable donors were in the group of donor with e-mail contact. Based on the findings of unfulfilled quality indicators further quality improvement objectives were defined for the future. Key words: transplantation, indicator, unrelated, donor registries, HLA typing

• MeSH
• časové faktory MeSH
• elektronická pošta MeSH
• homologní transplantace MeSH
• korespondence jako téma MeSH
• kostní dřeň MeSH
• lidé MeSH
• nepříbuzný dárce statistika a číselné údaje   MeSH
• registrace * normy   statistika a číselné údaje   MeSH
• řízení kvality MeSH
• testování histokompatibility MeSH
• transplantace hematopoetických kmenových buněk * MeSH
• ukazatele kvality zdravotní péče * MeSH
• žijící dárci MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• hodnotící studie MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika MeSH

AIMS: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. METHODS AND RESULTS: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. CONCLUSION: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.

• MeSH
• kardiologie * MeSH
• lékařská onkologie MeSH
• lidé MeSH
• nádory * terapie   MeSH
• ukazatele kvality zdravotní péče MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

BACKGROUND AND PURPOSE: Rigorous and regular evaluation of defined quality indicators is crucial for further improvement of both technical and clinical results after mechanical thrombectomy (MT) for acute ischemic stroke (AIS). Following the recent international multi-society consensus quality indicators, we aimed to assess trend in these indicators on national level. MATERIAL AND METHODS: The prospective multicenter study (METRICS) was conducted in Czech Republic (CR) in year 2019. All participating centers collected technical and clinical data including defined quality indicators and results were subsequently compared with those from year 2016. RESULTS: In the 2019, 1375 MT were performed in the CR and 1178 (86%) patients (50.3% males, mean age 70.5 ± 13.0 years) were analyzed. Recanalization (TICI 2b-3) was achieved in 83.7% of patients and 46.2% of patients had good 3-month clinical outcome. Following time intervals were shortened in comparison to 2016: "hospital arrival - GP" (77 vs. 53 min; p<0.0001), "hospital arrival - maximal achieved recanalization" (122 vs. 93 min; p<0.0001), and "stroke onset - maximal achieved recanalization" (240 vs. 229 min; p p<0.0001). More patients with tandem occlusion were treated in 2019 (7.8 vs. 16.5%; p<0.0001) and more secondary transports were in 2019 (31.3 vs. 37.8%; p=0.002). No difference was found in 3-month clinical outcome and in the rate of periprocedural complications. Results of the METRICS study met all criteria of multi-society consensus quality indicators. CONCLUSION: Nationwide comparison between 2016 and 2019 showed improvement in the key time intervals, but without better overall clinical outcomes after MT.

• MeSH
• benchmarking MeSH
• cévní mozková příhoda * diagnostické zobrazování   terapie   MeSH
• ischemická cévní mozková příhoda * MeSH
• ischemie mozku * diagnostické zobrazování   terapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• prospektivní studie MeSH
• retrospektivní studie MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• trombektomie škodlivé účinky   metody   MeSH
• ukazatele kvality zdravotní péče MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• Geografické názvy
• Česká republika MeSH

The European Society of Gastrointestinal Endoscopy (ESGE) and United European Gastroenterology (UEG) have a vision to create a thriving community of endoscopy services across Europe, collaborating with each other to provide high quality, safe, accurate, patient-centered and accessible endoscopic care. Whilst the boundaries of what can be achieved by advanced endoscopy are continually expanding, we believe that one of the most fundamental steps to achieving our goal is to raise the quality of everyday endoscopy. The development of robust, consensus- and evidence-based key performance measures is the first step in this vision.ESGE and UEG have identified quality of endoscopy as a major priority. This paper explains the rationale behind the ESGE Quality Improvement Initiative and describes the processes that were followed. We recommend that all units develop mechanisms for audit and feedback of endoscopist and service performance using the ESGE performance measures that will be published in future issues of this journal over the next year. We urge all endoscopists and endoscopy services to prioritize quality and to ensure that these performance measures are implemented and monitored at a local level, so that we can provide the highest possible care for our patients.

• MeSH
• delfská metoda MeSH
• gastrointestinální endoskopie normy   MeSH
• lidé MeSH
• společnosti lékařské MeSH
• ukazatele kvality zdravotní péče normy   MeSH
• zajištění kvality zdravotní péče metody   organizace a řízení   MeSH
• zlepšení kvality organizace a řízení   normy   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• konsensus - konference MeSH
• práce podpořená grantem MeSH
• směrnice pro lékařskou praxi MeSH
• Geografické názvy
• Evropa MeSH

This study examined the influence of perfectionistic strivings and perfectionistic concerns on athlete burnout and two key indicators of overtraining syndrome (training distress and subjectively perceived sports performance) using cross-sectional (N = 228), short-term (a 3-month interval, N = 93) and long-term (a 1-year interval, N = 83) longitudinal designs on a sample of adolescent athletes. In the cross-sectional analyses, sequential regressions revealed that perfectionism was a significant predictor of athlete burnout and both indicators of overtraining. In the three-month longitudinal perspective, both dimensions of perfectionism (strivings and concerns) contributed to the prediction of change in burnout and sports performance, but not training distress. When the one-year longitudinal relationships were regarded, only perfectionistic strivings significantly predicted decrease in burnout, and, for sports performance, the predictive power of both dimensions of perfectionism was even more pronounced when compared to the three-month longitudinal data.

• MeSH
• duševní vyhoření psychologie   MeSH
• lidé MeSH
• longitudinální studie MeSH
• mladiství MeSH
• mladý dospělý MeSH
• perfekcionismus * MeSH
• průřezové studie MeSH
• psychický stres MeSH
• sportovci psychologie   MeSH
• sportovní výkon psychologie   MeSH
• Check Tag
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Česká republika MeSH

OBJECTIVE: Cognitive decline is a key characteristic of Huntington's disease (HD). This study aimed to investigate the diagnostic accuracy of a cognitive battery with six tests used by most HD research centers to assess cognitive impairment in HD. METHOD: In total, 106 HD patients in different disease stages with more (HD-CD, N = 30) and less cognitive impairments (HD-NC, N = 70) and 100 healthy controls (NC) were matched by age, sex, and education and were examined using a standardized protocol including cognitive, motor, and functional assessments. RESULTS: One-way between-groups analysis of variance showed that controls performed significantly better than HD patients and that HD-NC significantly outperformed HD-CD patients in all cognitive tests (NC > HD-NC > HD-CD), with all Games-Howell post-hoc tests p < .001. Analyses using area under the receiver-operating characteristic curve (AUC) disclosed the diagnostic accuracy of all tests included in the battery to discriminate between NC and HD patients with AUC ranging from 0.809 to 0.862 (all p < .001) and between HD-CD and HD-NC patients with AUC ranging from 0.833 to 0.899 (all p < .001). In both analysis, Stroop Color Naming Test showed the highest discriminative potential. Additional analyses showed that cognitive deficits in all domains progressed with disease duration. Moreover, cognitive performance correlated with the severity of motor and functional impairment (all p < .001) and with the Disease Burden Score regardless of disease duration and age. CONCLUSION: Our results indicate that the cognitive battery is a suitable tool for assessing cognitive impairment in HD.

• MeSH
• Huntingtonova nemoc * komplikace   diagnóza   MeSH
• kognice MeSH
• lidé MeSH
• neuropsychologické testy MeSH
• osobní újma zaviněná nemocí MeSH
• tělesná a funkční výkonnost MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH